Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma

Klinicka Onkologie

Volumn 24, Issue 4, 2011, Pages 281-286

  Kessler, Petr ^a   Pour, L ^b   Gregora, E ^c   Zemanova, M ^d   Penka, M ^b   Brejcha, M ^e   Adam, Z ^b   Bacovsky, J ^d   Fenclova, M ^f   Frankova, H ^a,g   Hausdorf, P ^h   Walterova, L ⁱ   Heinzova, V ^j   Holikova, M ⁱ   Krejci, M ^b   Kubackova, K ^k   Langrova, E ^f   Maisnar, V ^l   Meluzinova, I ^m   Stavarova, Y ⁿ   Straub, J ^o   Scudla, V ^d   Gumulec, J ^p   Ullrychova, J ^q   Hajek, R ^b   more..

^a Hospital Pelhrimov   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^e Hospital Novy Jicin   (Czech Republic)

^f Nemocnice Kladno   (Czech Republic)

^g Hospital Trebic   (Czech Republic)

^h Department of Internal Medicine   (Czech Republic)

ⁱ Regional Hospital   (Czech Republic)

^j Department of Haematology   (Czech Republic)

^k UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^l UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^m Hospital Boskovice   (Czech Republic)

ⁿ T Bata's Regional Hospital   (Czech Republic)

^o CHARLES UNIVERSITY   (Czech Republic)

^p UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^q Hospital Decin   (Czech Republic)

more..

Author keywords

Low molecular weight heparin; Multiple myeloma; Prevention; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FIBRINOGEN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; THALIDOMIDE; VINCRISTINE; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CENTRAL VENOUS CATHETER; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG MEGADOSE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INCIDENCE; LUNG EMBOLISM; LUNG VENTILATION PERFUSION RATIO; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PARTIAL THROMBOPLASTIN TIME; PHLEBOGRAPHY; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; TREATMENT CONTRAINDICATION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RISK FACTORS; VENOUS THROMBOSIS;

EID: 80052212354     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Deitcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semm Thromb Hemost 2003; 29(3): 247-258. (Pubitemid 36776187)
2. Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98(5): 1614-1615.
3. Bowcock S, Rassam SM, Ward SM et al. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002; 7(1): 51-53. (Pubitemid 34692987)
4. Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89(7): 826-831. (Pubitemid 38981342)
5. Srkalovic G, Cameron MG, Rybicki L et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101(3): 558-566. (Pubitemid 38970607)
6. Sallah S, Husain A, Wan J et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15(10): 1490-1494. (Pubitemid 39409739)
7. Zangari M, Siegel E, Barlogie B et al.Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy Blood 2002; 100(4): 1168-1171.
8. Zangari M, Barlogie B, Anaissie E et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126(5): 715-721. (Pubitemid 39221309)
9. Zangari M, Barlogie B, Thertulien R et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003; 4(1): 32-35. (Pubitemid 36826874)
10. Rajkumar SV, Blood E, Vesole D et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24(3): 431-436. (Pubitemid 46630462)
11. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357(21): 2123-2132. (Pubitemid 350146107)
12. Minnema MC, Fijnheer R, De Groot PG et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1(3): 445-449.
13. Auwerda JJ, Sonneveld P, de Maat MP et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007; 92(2): 279-280. (Pubitemid 46852441)
14. Zangari M, Saghafifar F, Anaissie E et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13(3): 187-192. (Pubitemid 35001883)
15. Eke F, Fink L, Tricot G et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134(4): 399-405. (Pubitemid 44079553)
16. Geerts WH, Berqqvist D, Pineo GF et al. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl 6): 381S-453S.
17. Martin MG, Vij R. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature. Clin Lymphoma Myeloma 2009; 9(4): 320-323.
18. Minnema MC, Breitkreuz I, Auwerda JJ et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18(12): 2044-2046. (Pubitemid 40028434)
19. Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106(1): 35-39. (Pubitemid 40967171)
20. Weber D, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21(1): 16-19.
21. Ikhlaque N, Seshadri V, Kathula S et al. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 2006; 81(6): 420-422. (Pubitemid 43787928)
22. Baz R, Li L, Kottke-Marchant K et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80(12): 1568-1574. (Pubitemid 41747058)
23. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106(13): 4050-4053. (Pubitemid 41775908)
24. Menon SP, Rajkumar SV, Lacy M at al Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 2008; 112(7): 1522-1528. (Pubitemid 351441164)
25. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myleoma: ransomised controlled trial. Lancet 2006; 367(9513): 825-831. (Pubitemid 43363369)
26. Falanga A, Russo L, Vignoli A et al. Prognostic significance for venous thromboembolism (VTE) of hemostatic markers in patients with multiple myeloma (MM) receiving thalidomide. J Thromb Haemost 2007; 5 (Suppl 2): P-M-507.
27. Palumbo A, Cavo M, Bringhen S et al. Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. J Clin Oncol; 2011; 29(8): 986-993.
28. Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 2007; 131(1): 275-277. (Pubitemid 46123003)
29. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22(2): 414-423.